Investments
25Portfolio Exits
2Funds
1About DROIA Ventures
DROIA Ventures is a venture investor that focuses exclusively on the development of oncology therapies. DROIA is dedicated to making a difference in the fight against cancer. The firm has adopted a unique investment model to accelerate development in its portfolio companies, the DROIACs.
Want to inform investors similar toDROIA Venturesabout your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
LatestDROIA VenturesNews
Mar 10, 2023
美国肌萎缩精准药物研发商，完成8800万美元B轮融资，投资方为Sanofi Ventures、Droia Ventures、EQT Life Sciences领投，INKEF Capital、Dementia Discovery Fund、Amgen、MP Healthcare Venture Management、三井物产环球投资、Dolby Family Ventures、Mission Bay Capital、Sanford Biosciences、LS Polaris Innovation Fund、ALS投资基金跟投。
DROIA Ventures Investments
25 Investments
DROIA Ventures has made25 investments.Their latest investment was inQurAlisas part of theirSeries BonMarch 3, 2023.
DROIA Ventures Investments Activity
Date |
轮 |
Company |
Amount |
New? |
Co-Investors |
Sources |
|---|---|---|---|---|---|---|
|
3/9/2023 |
Series B |
QurAlis |
$88M |
No |
ALS Investment Fund,Amgen Ventures,Dementia Discovery Fund,Dolby Family Ventures,DROIA Ventures,EQT Life Sciences,INKEF Capital,Mission Bay Capital,Mission BioCapital,Mitsui & Co. Global Investment,MP Healthcare Venture Management,Polaris Partners,Sanford Biosciences,Sanofi Ventures,和SV Health Investors |
10 |
|
3/7/2023 |
Series A |
Volastra Therapeutics |
$60M |
No |
3 |
|
|
7/28/2022 |
Series A |
Vicinitas Therapeutics |
$65M |
Yes |
3 |
|
|
1/6/2022 |
Series A |
|||||
|
7/12/2021 |
Series B |
Date |
3/9/2023 |
3/7/2023 |
7/28/2022 |
1/6/2022 |
7/12/2021 |
|---|---|---|---|---|---|
轮 |
Series B |
Series A |
Series A |
Series A |
Series B |
Company |
QurAlis |
Volastra Therapeutics |
Vicinitas Therapeutics |
||
Amount |
$88M |
$60M |
$65M |
||
New? |
No |
No |
Yes |
||
Co-Investors |
ALS Investment Fund,Amgen Ventures,Dementia Discovery Fund,Dolby Family Ventures,DROIA Ventures,EQT Life Sciences,INKEF Capital,Mission Bay Capital,Mission BioCapital,Mitsui & Co. Global Investment,MP Healthcare Venture Management,Polaris Partners,Sanford Biosciences,Sanofi Ventures,和SV Health Investors |
||||
Sources |
10 |
3 |
3 |
DROIA VenturesPortfolio Exits
2 Portfolio Exits
DROIA Ventureshas2portfolioexits. Their latest portfolio exit wasCyteir Therapeutics onJune 18, 2021.
Date |
Exit |
Companies |
Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.
|
Acquirer |
Sources |
|---|---|---|---|---|---|
|
6/18/2021 |
IPO |
Public |
1 |
||
Date |
6/18/2021 |
|
|---|---|---|
Exit |
IPO |
|
Companies |
||
Valuation |
||
Acquirer |
Public |
|
Sources |
1 |
DROIA VenturesFund History
1 Fund History
DROIA Ventureshas1 fund, includingDroia Ventures Fund III.
Closing Date |
Fund |
Fund Type |
Status |
Amount |
Sources |
|---|---|---|---|---|---|
|
5/11/2021 |
Droia Ventures Fund III |
|
|
$265M |
2 |
Closing Date |
5/11/2021 |
|---|---|
Fund |
Droia Ventures Fund III |
Fund Type |
|
Status |
|
Amount |
$265M |
Sources |
2 |
DROIA VenturesTeam
2 Team Members
DROIA Ventureshas2 team members,includingcurrent Managing Partner, Janwillem Naesens.
Name |
Work History |
Title |
Status |
|---|---|---|---|
|
Janwillem Naesens |
Waterland Private Equity Investments,和McKinsey & Company |
Managing Partner |
Current |
Name |
Janwillem Naesens |
|
|---|---|---|
Work History |
Waterland Private Equity Investments,和McKinsey & Company |
|
Title |
Managing Partner |
|
Status |
Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.